We have located links that may give you full text access.
CASE REPORTS
JOURNAL ARTICLE
Diaphragmatic rupture, a new complication of Bevacizumab.
European Journal of Surgical Oncology 2012 November
INTRODUCTION: Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor has demonstrated a significant benefit on overall survival (OS) and progression free survival (PFS) in patients with metastatic colorectal carcinoma. Many adverse effects of Bevacizumab are well-known. We report here the first case of diaphragmatic perforation after Bevacizumab treatment.
PATIENTS AND METHODS: A case of Bevacizumab induced diaphragmatic perforation was reported and a search of PubMed and Cochrane databases was performed in order to review relevant literature on the adverse effects of Bevacizumab.
DISCUSSION: Serious late surgical complications may occur even if the delay between surgery and Bevacizumab treatment is respected. These complications may be life threatening for patients, and demonstrate the importance of careful monitoring after postoperative administration of Bevacizumab.
PATIENTS AND METHODS: A case of Bevacizumab induced diaphragmatic perforation was reported and a search of PubMed and Cochrane databases was performed in order to review relevant literature on the adverse effects of Bevacizumab.
DISCUSSION: Serious late surgical complications may occur even if the delay between surgery and Bevacizumab treatment is respected. These complications may be life threatening for patients, and demonstrate the importance of careful monitoring after postoperative administration of Bevacizumab.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app